North America Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Analysis, and Others), Therapeutic Application (Oncology, Infectious Diseases, Neurological Disorders, Autoimmune Diseases, Gynecological Disorders, Cardiovascular Diseases, Respiratory Disorders, and Others), and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization, and Others)
The North America pharmacokinetics services market was valued at US$ 375.36 million in 2023 and is expected to reach US$ 692.77 million by 2031; it is estimated to register a CAGR of 8.0% from 2023 to 2031.
Expanding Range of Application of Pharmacokinetic Studies Fuels North America Pharmacokinetics Services Market
Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level, no-observed effect level (NOEL), and pharmacokinetic/pharmacodynamic testing. The main focus of any pre-clinical program conducted is to support the analysis of a safe and effective dose range for testing in pharmacokinetic studies. Several toxicology studies conducted data on the NOEL, i.e., the highest dose that does not produce adverse effects. This dose level is further converted to a HED level on a comparative body-surface area basis if there is lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted in hospitals. The PK model is often applied to determine exposure to drugs, concentrations of drugs to analyze optimal dosage, and analyze the disposition of drugs in the human body. Healthcare providers implement the principles of PK to design monitor drug concentrations, doses of some drugs, maximize the intended therapeutic outcomes and minimize toxicities.
North America Pharmacokinetics Services Market Overview
The US accounts for the largest share of the North America pharmacokinetics services market in North America. The country has emerged as a leading clinical research destination; it accounts for ~50% of the total clinical trials conducted in the world. The availability of established medical infrastructure, fast approval timelines, and favorable regulatory framework create a conducive environment for pharmaceutical research companies to conduct clinical trials. Moreover, the data generated in trials conducted in the US is accepted globally. As per a World Health Organization (WHO) report, the US registered the highest number of clinical trials (157,618) in 2021.
North America Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)
North America Pharmacokinetics Services Market Segmentation
The North America pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.
Based on drug type, the North America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.
In terms of service type, the North America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.
By therapeutic application, the North America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.
By end user, the North America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.
By country, the North America pharmacokinetics services market is segmented into the US, Canada, and Mexico. The US dominated the North America pharmacokinetics services market share in 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the North America pharmacokinetics services market.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pharmacokinetics Services Market Landscape
4.1 PEST Analysis
5. North America Pharmacokinetics Services Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Chronic and Infectious Diseases
5.1.2 Expanding Range of Application of Pharmacokinetic Studies
5.1.3 Outsourcing of Pharmacokinetics Services to CROs
5.2 Market Restraints
5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.3 Market Opportunities
5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.4 Future Trend
5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.5 Impact of Drivers and Restraints:
6. Pharmacokinetics Services Market - North America Analysis
6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
7. North America Pharmacokinetics Services Market Analysis - by Drug Type
7.1 Overview
7.2 Small Molecule
7.2.1 Overview
7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
7.3.1 Overview
7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
7.4.1 Overview
7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. North America Pharmacokinetics Services Market Analysis - by Service Type
8.1 Overview
8.2 Pre-Clinical ADME and Human Studies
8.2.1 Overview
8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 PK/PD Analysis and Reporting
8.3.1 Overview
8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Dosing Simulations
8.4.1 Overview
8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Risk Analysis
8.5.1 Overview
8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
9.2.1 Overview
9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
9.3.1 Overview
9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
9.5.1 Overview
9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
9.6.1 Overview
9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
9.7.1 Overview
9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. North America Pharmacokinetics Services Market Analysis - by End User
10.1 Pharmaceutical and Biotechnology Companies
10.1.1 Overview
10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
10.2.1 Overview
10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Others
10.3.1 Overview
10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11. North America Pharmacokinetics Services Market - Country Analysis
11.1 North America
11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User
12. Company Profile
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Eurofins Scientific SE
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Evotec SE
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Certara Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.5 Parexel International Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Allucent
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 PACIFIC BIOLABS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SGS SA
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms for Pharmacokinetic Services Market
List of Tables
Table 1. North America Pharmacokinetics Services Market Segmentation
Table 2. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 11. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 12. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 13. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 14. Glossary of Terms
List of Figures
Figure 1. North America Pharmacokinetics Services Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. North America Pharmacokinetics Services Market - Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 6. North America Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 7. Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. North America Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 11. Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. North America Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 17. Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 25. North America Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 26. Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America Pharmacokinetics Services Market by Key Countries - Revenue (2023) (US$ Million)
Figure 30. North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 31. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
Figure 33. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- Evotec SE
- Certara Inc.
- Parexel International Corp
- Thermo Fisher Scientific Inc.
- Allucent
- PACIFIC BIOLABS
- SGS SA
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.